Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
27
betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
placebo tablets b.i.d., six weeks treatment
Site Reference ID/Investigator# 63545
Singapore, Singapore
Site Reference ID/Investigator# 63544
Singapore, Singapore
Cerebral Blood Flow (CBF)
To explore the sustained effect of betahistine on the cerebral blood flow (CBF) in the whole brain.
Time frame: 6 weeks
Regional Cerebral Blood Flow (rCBF)
To explore the sustained effect of betahistine on the regional cerebral blood flow (rCBF) in pre-determined regions of interest.
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.